Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction gefitinib followed by cisplatin + docetaxel chemoradiotherapy for EGFR-mutated locally advanced non-small cell lung cancer
jRCTs071180036Phase 2Completed
- Start
- Apr 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib, cisplatin and docetaxel in non-small cell lung cancer (NSCLC). Primary endpoint: Two-year overall survival rate. Started Apr 2011; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180036.